

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY DOCKET NO. P08898US00/BAS
INTERNATIONAL APPLICATION NO. PCT/IB04/03146	INTERNATIONAL FILING DATE 28 September 2004	US APPL. NO. (If known, see 37CFR 1.5) 10/573,804
TITLE OF INVENTION: IDENTIFICATION OF POLYMORPHISMS IN THE EPCR GENE ASSOCIATED WITH...		
APPLICANT(S) FOR DO/EO/US: AIACH		
Applicant herewith submits to the US Designated/Elected Office (DO/EO/US) the following items and other information:		
<p><input type="checkbox"/> 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p><input checked="" type="checkbox"/> 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 USC 371.</p> <p><input type="checkbox"/> 3. This is an express request to begin national examination procedures (35 USC 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p><input type="checkbox"/> 4. The US has been elected (Article 31).</p> <p><input type="checkbox"/> 5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) <ul style="list-style-type: none"> <input type="checkbox"/> a. is attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> b. has been communicated by the International Bureau <input type="checkbox"/> c. is not required, as the application was filed in the United States Receiving Office (RO/US). </p> <p><input type="checkbox"/> 6. An English translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ul style="list-style-type: none"> <input type="checkbox"/> a. is attached hereto. <input type="checkbox"/> b. has been previously submitted under 35 U.S.C. 154(d)(4). <input type="checkbox"/> c. is not needed since the International Application is in English. </p> <p><input type="checkbox"/> 7. Amendments to the claims of the International Appln. under PCT Article 19 (35 USC 371 (c)(3)) <ul style="list-style-type: none"> <input type="checkbox"/> a. are attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> b. have been communicated by the International Bureau. <input type="checkbox"/> c. have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> d. have not been made and will not be made. </p> <p><input type="checkbox"/> 8. An English translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p><input checked="" type="checkbox"/> 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p><input type="checkbox"/> 10. An English translation of the annexes to the Int'l Pre. Exam. Report under PCT Article 36 (35 USC 371(c)(5)).</p>		
<p>Items 11. to 20. below concern document(s) or information included:</p> <p><input checked="" type="checkbox"/> 11. An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.</p> <p><input type="checkbox"/> 12. An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 & 3.31 is included.</p> <p><input checked="" type="checkbox"/> 13. A preliminary amendment.</p> <p><input type="checkbox"/> 14. An Application Data Sheet under 37 CFR 1.76.</p> <p><input type="checkbox"/> 15. A substitute specification.</p> <p><input type="checkbox"/> 16. A power of attorney and/or change of address letter.</p> <p><input checked="" type="checkbox"/> 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 & 37 CFR 1.821-825.</p> <p><input type="checkbox"/> 18. A second copy of the published international application under 35 USC 154(d)(4).</p> <p><input type="checkbox"/> 19. A second copy of the English translation of the international application under 35 USC 154(d)(4).</p>		
<p>20. Other items or information:</p> <p><input type="checkbox"/> Return Receipt Postcard.</p> <p><input checked="" type="checkbox"/> A copy of the Notification of Missing Requirements under 35 U.S.C. 371.</p> <p><input checked="" type="checkbox"/> In the event that a petition for extension of time is required to be submitted herewith, and in the event that a separate petition does not accompany this response, applicant hereby petitions under 37 CFR 1.136(a) for an extension of time of as many months as are required to render this submission timely. Any fee is authorized in 21(c).</p> <p><input type="checkbox"/></p>		

U.S. APPLICATION NO. (If known) 10/573,804	INTERNATIONAL APPLICATION NO. PCT/IB04/03146	ATTORNEY DOCKET NO. P0889US00/BAS	
The following fees have been submitted:		CALCULATIONS	
<input type="checkbox"/> 21. Basic national fee (37 CFR 1.492(a))		\$300	
<input type="checkbox"/> 22. Examination fee (37 CFR 1.492(c))			
<input type="checkbox"/> Written Opinion or IPER by US indicates all claims satisfy PCT Art. 33(1-4)		\$0	
<input type="checkbox"/> All other situations		\$200	
<input type="checkbox"/> 23. Search fee			
<input type="checkbox"/> Written Opinion or IPER by US indicates all claims satisfy PCT Art. 33(1-4)		\$0	
<input type="checkbox"/> Has been paid on the Int'l Appln. to the USPTO as ISA		\$100	
<input type="checkbox"/> International Search Report prepared and provided to the Office		\$400	
<input type="checkbox"/> All other situations		\$500	
TOTAL OF 21, 22 AND 23		\$	
<input type="checkbox"/> SIZE FEE: sheets - 100 = ÷ 50 = [rounded up] × \$250 =		\$	
<input type="checkbox"/> Surcharge of \$130 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e))		\$130	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total Claims	11 - 20 =	0	X \$50 =
Independent Claims	3 - 03 =	0	X \$200 =
<input type="checkbox"/> Multiple Dependent Claim(s) (if applicable)		+ \$360 =	\$
TOTAL OF ABOVE CALCULATIONS		\$130	
<input type="checkbox"/> Applicant claims small entity status - 37 CFR 1.27. Fees above reduced by ½.		\$	
SUBTOTAL		\$130	
<input checked="" type="checkbox"/> Fee for Extension of Time		\$120	
TOTAL NATIONAL FEE		\$	
<input type="checkbox"/> Fee for recording enclosed assignment (37 CFR 1.21(h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31)		\$40 per property	\$
TOTAL FEES ENCLOSED		\$250	
05/23/2007 MKAYPAGH 00000020 10573804		Amount to be	Refunded \$
01 FC:1617 130.00 0P			Charged \$
<input checked="" type="checkbox"/> Payment of \$250 is made by attached Credit Card Payment Form (PTO-2038) <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required for this submission (except claims fees if the box below is checked) or credit any overpayment to Deposit Account No. 12-0555. <input type="checkbox"/> Do not charge any claim fees now - any additional claims fees will be paid with the Missing Requirements.			
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
POWER OF ATTORNEY & CORRESPONDENCE ADDRESS: CUSTOMER NO. 00881	NAME: B. Aaron Schulman REG. NO.: 31,877 Signed (for) by:  REG. NO.: 31,877		
Date: May 21, 2007			

**PETITION FOR
EXTENSION OF TIME
UNDER 37 CFR 1.136(a)**

Application #	10/573,804
Confirmation #	9377
Filing Date	March 28, 2006
First Inventor	AIACH
Art Unit	
Examiner	
Docket #	P08898US00/BAS

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and fee under 37 CFR 1.17(a) are as follows.

NOTE: Applicant claims small entity status.

cc COPY

No extension of time previously obtained.

<u>Time Period</u>	<u>Large Entity Fee</u>	<u>Small Entity Fee</u>
<input checked="" type="checkbox"/> One month	<input checked="" type="checkbox"/> \$ 120	<input type="checkbox"/> \$ 60
<input type="checkbox"/> Two months	<input type="checkbox"/> \$ 450	<input type="checkbox"/> \$ 225
<input type="checkbox"/> Three months	<input type="checkbox"/> \$ 1020	<input type="checkbox"/> \$ 510
<input type="checkbox"/> Four months	<input type="checkbox"/> \$ 1590	<input type="checkbox"/> \$ 795
<input type="checkbox"/> Five months	<input type="checkbox"/> \$ 2160	<input type="checkbox"/> \$ 1080

- Payment by credit card. FORM PTO-2038 in the amount of \$250 is attached.
- The Director is authorized to charge any fee or additional fee due in connection herewith to Deposit Account No. 12-0555:
 - (1) if no payment or an insufficient payment is enclosed and a fee is due in connection herewith; or
 - (2) if a further fee and petition for extension of time are required at this time - and in this event, applicant hereby petitions under 37 CFR 1.136(a) for any further extension of time of as many months as are required to render this submission timely.

Date: May 21, 2007


05/23/2007 MKAYPAGH 00000020 10573804

02 FC:1251

Signed By

120.00 AM

Attorney of Record


Name: B. Aaron Schulman
Registration No.: 31,877

STITES & HARBISON PLLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314
TEL: 703-739-4900 • FAX: 703-739-9577 • CUSTOMER No. 00881

PRELIMINARY AMENDMENT	Application #	10/573,804
	Confirmation #	9377
	Filing Date	03/28/06
	First Inventor	AIACH
	Art Unit	
	Examiner	
	Docket #	P08898US00/BAS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

 COPY

SIR:

Prior to examination

A) please consider the responsive **Remarks** and **Statement** provided herewith in

Attachment A; and

B) please amend the above identified application as follows:

- After page 29, please insert the **attached sequence listing** and substitute this listing for the one originally filed.
- A **Computer Readable Form** of the sequence listing is also provided.
- **Amendments to the Claims** are reflected in the listing of the claims provided herewith in **Attachment B**.

In view of the amendments made and the remarks provided, it is submitted that the present application is now in condition for examination and allowance.

Respectfully submitted,


By: B. Aaron Schulman
Registration No.: 31,877

Date: May 21, 2007

STITES & HARBISON PLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314
TEL: 703-739-4900 • FAX: 703-739-9577 • CUSTOMER No. 000881

ATTACHMENT A

REMARKS

By the present amendment, a sequence listing and diskette in suitable US form are now provided. Applicants state as follows:

STATEMENT

Applicants state in accordance with 37 C.F.R. § 1.821(f) that the content of the enclosed paper sequence listing and computer readable form are the same, and that in accordance with 37 C.F.R. § 1.821(g), the enclosed submission contains no new matter.

Applicants submit that this application is now in compliance with sequence listing requirements. The claims have also been amended to eliminate multiple dependencies.

Accordingly, Applicants submit that the present application is now in condition for examination and allowance.

END OF REMARKS

 COPY

ATTACHMENT B
Amendments to the Claims

COPY

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Original) An *in vitro* method for determining the risk of developing thrombosis in a subject, which method comprises identifying polymorphisms of EPCR gene on at least one of positions 1651, 3610, 4216, and 6936 (SEQ 10 NO:1), wherein the presence of G at position 1651, C at position 3610, A at position 4216, or G at position 6936 is indicative of a higher risk to develop thrombosis in comparison with a control subject that does not show the same polymorphisms.

2. (Original) An *in vitro* method according to claim 1, which method comprises identifying polymorphisms of EPCR gene at positions 1651, 3610, 4216, 6936, 3787, 3877, 4868, 5233, 5760, 6333, 7014, 7968, 7999 of SEQ 10 NO: 1, wherein the simultaneous presence of :
 - G at position 1651
 - C at position 3610
 - A at position 4216
 - G at position 6936
 - C at position 3787
 - G at position 3877
 - T at position 4868
 - G at position 5233
 - T at position 5760

- T at position 6333
- G at position 7014
- A at position 7968
- G at position 7999

DC COPY

are designated A3 haplotype and, when present on at least one allele, are indicative of a higher risk to develop thrombosis in comparison with a control subject without any A3 allele.

3. (Currently Amended) The method according to claim 1-~~or 2~~, wherein said thrombosis is a venous thrombosis.
4. (Currently Amended) The method according to ~~any of~~ claims 1-to-3, wherein the analysis is undertaken on genomic DNA that is extracted from a biological sample of the subject.
5. (Currently Amended) The method according to ~~any of~~ claims 1-to-4, wherein the analysis comprises a step of amplification of the genomic DNA.
6. (Currently Amended) The method according to ~~any of~~ claims 1-to-5, wherein the polymorphisms of the EPCR gene are identified by sequencing.
7. (Currently Amended) The method according to ~~any of~~ claims 1-to-6, wherein at least one of the polymorphisms of the EPCR gene is identified by RFLP analysis.

8. (Original) The method according to claim 7, comprising identifying the polymorphism of EPCR gene on position 6936, by creating a restriction site for endonuclease PstI by amplification of the EPCR gene with mutagenic primers, when the amplified fragment contains an A at position 6936, so that when the amplified fragment containing a G, it remains undigested.

9. (Original) An isolated nucleic acid encoding the EPCR receptor, that comprises SEQ ID NO:2.

10. (Currently Amended) A kit suitable for the methods according to any of claims 1 to 6, which kit comprises a pair of nucleotide primers specific for amplifying all or part of the EPCR gene comprising at least one of positions 1651,3610,4216 of SEQ ID NO:1.

11. (Original) A method for genotyping the EPCR gene, which method comprises identifying the polymorphism of the EPCR gene at position 4216 (SEQ ID NO: 1), wherein the presence of C at position 4216 shows the A1 haplotype, the presence of G at position 4216 shows the A2 haplotype, and the presence of A shows the A3 haplotype.

SEQUENCE LISTING

C COPY

<110> AIACH et al.

<120> Identification of polymorphisms in the EPCR gene
associated with thrombotic risk

<130> P08899US00/BAS

<140> 10/573,804

<141> 2006-03-28

<160> 18

<170> PatentIn Ver. 2.1

<210> 1

<211> 8167

<212> DNA

<213> Homo sapiens

<400> 1

aatgaaata tttcaggctg tgcacagtgg ctcaaggcttg taatccacgc atgttgggag 60
gctgaagtgg gcggatcacc tgaggtcagg agttttagac caacctggcc aacatggta 120
aatcccatct ctactaaaaaa tacaaaaatt agccaggtgt ggtggcagggt gactgtaatc 180
ccagctactt gggaggctga ggcaggagaa tcgcttgaat ctgggagggtt gaggttgcag 240
tgagccgaga tcacgcccact gcatacagca agactccatc tcaaaaaaaaaaaaaaaa 300
aagaaaaaaaaa aaatgtttca taatttttaa taaaaggcaaa gacaatataaa attggtagtt 360
attnaagtca ttctactttt cctgaggccc agtgcaggaa aacaaagtcc ctatcctgt 420
tccaaactaga ccattttgat aagctgcaaa aagaaaaagac ttgtatgcta ttcttagcc 480
agtttgcaac agctgagagg tgagcatgga agctttgca tatattcagt tcagagaatg 540
ggtgcttagt ttatgtccag agtttgcctt agatttcaact atgacgtcag ctctccgggg 600
agaagtagat aaaaataaaaaa gttaaaatcc ctctcagtc tttaccataat cctattcccc 660
agaggtaatc tctattgaca gtacccctcc agatatttc cctatgtata tacaataaca 720
cagatacaca ctgaaagtta attttggcca ggtgcagtgg ctctgccta taccagagga 780
ttgctttagt gcaggagttc aagaccagcc tggcaacat agcagacca catctctagt 840
aaaaataaaaaa aaaaataatgc taggcgtggt ggcacagtgg cacgtacctt tagtctcagc 900
tactcgggtt gttgagggtgg gagaatcaact tgagccccc aggtcaagcc tacaattagc 960
tgtgattgct tcactgcact atagcctggg caacagagct agaccctgtc tcaaaaaaaaaat 1020
ataataataat tttatataatata tatatgagga tgaaattaca tatgtattat ttgaacagaa 1080
gtgaaatctt ttcttttttt tttcagaca gaatcttgc gcacgttccca ggctagaatg 1140
cagtgggtgt atctcggccc tctgcacact ccacccccc ggttcaagcg attctcatgc 1200
ctcgggtctcc caagtagctg gattacagg catgcaccac catgcccagc taattttgt 1260
atttttcgta gagacgttgc ccatattggc caggctggc tcaaaactcctt ggcctcaagt 1320
gatctgccc cctcggcctc ccaaagtggc agcagcatgc tcggaggaggt gactttaaag 1380
cttttctact tgcttccatg agtaaggagc gcattttaca ctgctatcca aaactcatca 1440
tagaaacata cacacacaaa accaaaggcac acatatacaa ctgagcaat atttcatgac 1500
ataaacactt ctcttactaa gggtgacgcg ctgaaatttt gtattctgtc ctatttcatt 1560
ttttaaaaat ggtaaccatg acctgctaaa ttgatttcat tgcactaa taaattatga 1620
cctcagtttcc aaaaagattt cttaggtaa ccaatcatct tctgagattt atacagattt 1680
ctcataattc tctccatattt tttaaaaaaca tgctgcagt gactgcttta cactcatttt 1740
atgactactt ctgagaccaa gatcccgat tatgtattt ttatattttt aaaaattctgg 1800
taaaatgttag ccattataact gaaaaactaa attttaatct tggatctgtc accaccatga 1860
tatataaaact ttgggcaagt ccctgcacact ctctgacactt caatctcccc atcagcaacc 1920
tgctgatcct actcccaagga gtgtgctcta agttgaaagt agatgccccca ccccccgtagt 1980
cagcgcggc aggacttctc accaaggccct tctcccccctt ttccgctccc tggatctgtt 2040
tccttaggaag cagcccaagg agaaggggaaa aggcagggtt gggcaggagg gagcaatgaa 2100
gggcggggca gaggaggggc aggagggagg ccggccccctt agtaggaaat gagacacagt 2160
agaaaataaca ctttataagc ctcttccctcc tcccatctcc tggatctgtt ccattccctt 2220
ctgcccagac tccgccccctc ccagacggc ctcacttctc ttttccctag actgcagcc 2280
gcggagcccg cagccggcccc gagccaggaa cccaggtccg gagcctcaac ttcaggatgt 2340

tgacaacatt gctgccgata ctgctgctgt ctggctggc cttttgtac caagacgcct 2400
cagatggta gtcggggca catctccgc ctcaggatgg ttctggagaa tctcagtcta 2460
tctggcaca tggcaagacc acaggagagc ttatctcaca gcatctgtgt ctgcagctgg 2520
ctagatctct ctacaggcga ggcagagtc tggggactgg ttcgtgtccc aaagccaagg 2580
tgagttaga catttaagcc cctgaaaagg gggagatgaa agaggctagg gaaaacagga 2640
tgactggaaa catgagaaag aaaccagcag agagggtagg agaatcagcc ccagggagag 2700
gggagaaagg ggaactgagg gtgatggtag ataggggtac atctagggga gacggagaaga 2760
ggctcagaag agaagagaaa tggagggaaat gggagaccc tggaaaact gatggaaagaa 2820
gtggggaaag agtggggcag agagaggta ggggaggcta gggaaaatgg aaggagactg 2880
gtcgcagctg gtggaaactgg ggagaaagag atgctgtgcc taatagaact tatggcgt 2940
caggctactg aagtggccct gtttaagcag aaaaggaggt tattaccctc cattataatt 3000
gcacaggggc ctcccttccc ctctctcaca atccccgtaa cttcagtc cccctcagag 3060
aggcagcaa taataaccag tattcaatga gtgctacta tggtaataac atgtattgac 3120
ccatttaact tgcacaaacc cctaaaggta ggtaatatta ttactatctc cattttatga 3180
ggaggaaact gggtcacaga gtagttaagg accatgtcta gggttatcca taaatataact 3240
tattcacatc tgcagataca aagcacaact tctcaatgc aaacacagac aggaccact 3300
cacacacaca gattacaac cccggactca tccaaatgtg ctctggcat caactctgtg 3360
ccagccttctt ttctgggtgt aggaagcaga gattaccaag catggttcca tagccttagag 3420
gagtcagtg tggctgtgt gtgttggag acagccaggt agtatccgt gagatacaca 3480
ctaataatgt gtggctggg atcactgaaa cagacacact gtgtctcggt gggcatcaga 3540
aaaaaaatttc caagaagagg gcaactgagc tgggtcttt tttctttgt tttctttctt 3600
tttctttttt tttttttttt tttttttttt agatggagtc ttgtgtgtc acccaggctg 3660
gaatgcagtg gcacaatttc agctaactgt aaccccaac tcccgaggttc aggcgattct 3720
cctgcctcag cctcctgagt agctggact acaggcatgt accaccacgc ctggctaata 3780
tttgtacttt tagtacagat ggggttgcg catgttggcc aggctggct tgaatccctg 3840
acctaagtg atccggccgc ctcggcctcc caaagtgtg ggattacagg catgagccac 3900
cgcgcccagt ctctgagctg ggtcttaaat catgaataaa cttcgccagg cagaaaaaagg 3960
gagggcagagc aatcctgaca tgctattcat gtgtcagcca aaggcagcat gaggaatccc 4020
aactagttt atatataagc agcgggaagc ggccagaaaa ggcagcaggg gccaggctc 4080
tagcagcctt gaatgccagg ctaaagactc tggacttgc tctgtgggg ggcagtgtag 4140
cagaatggct gagtgctgga cttgactgcc tacgtcaaa cttggctct gctacactat 4200
ctctgtctca gtttcgcatg tagactgggg ttaataatag tagtattgc attaagccac 4260
tggggaaagg cacaagata ataatgtatg taaagccat tgcccaggtt ataataagca 4320
ctgaatcgac attggctatg attatttttt attaatgaag gggaggggg tatggcactg 4380
gaagattttt agtaggaaaa ggacatgatc tcatccctgg gtcaggtgaa ggtcggaaata 4440
gagaacgggg agatgaagta gaaagttact accccagtct agatgagacg gatgaatct 4500
gaatcagggc agtggaaagag gagatggaga acaggcgtt gaatttggaaat tttattcagg 4560
tcaggatttg ttaaccattt gttccgttgg ttaacaggaa acggggggag ggagagccga 4620
gggtaaaaaa ggaggcagaa aggagtgtct cttccactgc aggctcagt ttcctcatct 4680
gtaaaaacgga gataataatc cctgtcctgt cctctggca gagttactgt cagcgtcaaa 4740
cgggagaagc ggtggggaggg cacattatag tttatgaagg gtcgagaagg cggcggccca 4800
gcctcgaggt agggggttat tatctccgc tgccccccgc cccctccac gccggcccg 4860
gctgaagttg actctgccc caggcctcca aagacttcat atgctccaga tctcctactt 4920
ccgcgacccc tatcacgtgt ggtaccagg caacgcgtcg ctggggggac acctaacgca 4980
cgtgctggaa ggcccagaca ccaacaccac gatcattcag ctgcagccct tgcaggagcc 5040
cgagagctgg ggcgcacgc agagtggct gcagtcctac ctgctccagttccacggcct 5100
cgtgcgcctg gtgcaccagg agcggacctt ggcctgtgag taggcgcgc gcgggggcgg 5160
ggtctggcg gggctagttgg gggcgggggc tggcgggtgg gggcgggggc tggcggatgg 5220
aggcgggctg gggcttgcag ggacccggca gccactggag ctgggtggcg cttggcctt 5280
tgaagatttc tgggtgggg ctggagagag gcagttgtcc cgcctaagaa agccccact 5340
cgggcggctg tcctgtggc ataacctttt gggatagacc ctgttggaa gcccgtacac 5400
cgtgacgtcg aaggccccca gaaaactctt caccctcgc ctcacagtcc tccaaactctt 5460
tttcttcata gatctccgtc cttcccttcc cacagcccccc agcaacttcac ccccccaccc 5520
ccagccactt ctcataacaag ctgatgactt cgcttttagt tccactcatg accccaaactc 5580
ttccccccaaa gaccccaagt tcttcctca aagccccact cttccccctt cacaacccta 5640
actcccttctt ctcaaaagacc ccaatttctt ttctcaaagc accaaggcacc actccgtccc 5700
cctcccccacca ccatcatggc ctttaattcc tttctctccct agtccccccac cccaccctt 5760
ttttttttt tttttttttt ttttttttgg acggagtctt gctctgtcg ccaggctgga 5820
gtgcagtggc gcgatctcggt ctcactgcaaa cttccgcctc cccgggttcaa gcgattctcc 5880
tgcctcagcc tcaccaagcag ctgggactac aggccccccg caccacgccc ggctaattttt 5940
ttgtatTTT agtagagacg gggtttcggcc atgttggcca ggctggctc gaactcctga 6000

cctcaggcga tccacaagcc tggcctccca aagtgtggg attacaggcg tgagctgccg 6060
ccccctgccc agcctcaccc cctgttttt ttttcttata cagttgaaca aggctgaca 6120
atccccttt ttcacacag tccctggccc cttctttctt agcctctaacc aggtctaacc 6180
caaacccttc ctacacagccc caggcccttc tccccatagt tccctgactt agactcccct 6240
ctcctcacag cactgactct tgccttc tgccttttc cccttgggtgg gcctcgcccc 6300
acacctggca ccctctctgc acagtcctt gatctgact gtctatccac agttctctg 6360
accatccgct gcttcctggg ctgtgagctg cctcccgagg gctctagagc ccatgtctc 6420
ttcgaagtgg ctgtgaatgg gagtcctttt gtgagttcc ggccggagag agccttgtgg 6480
caggcagaca cccaggtcac ctccggagtg gtcacccctca ccctgcagca gctcaatgcc 6540
tacaaccgca ctggtatga actgcgggaa ttccctggagg acacctgtgt gcagttatgtg 6600
cagaaacata ttcccgccga aaacacgaaa ggtatgtatgg gacggggccc aggctgc当地 6660
gctggggaga gggcggttc cagacaaatg gatggacccctg aaggatggat gcctagagca 6720
acaagaggcc cacagctggg ggtttgggac agaacacacg cagcttcagt cagttgtt 6780
acgggtccct ttccctctggg gcagaaaacgc tttggggttt gactcaaatac atggactct 6840
tgggggccta ttcccgccgc taactctttt catgttctgc agggagccaa acaagccgct 6900
cctacacttc gctggtcctg ggcgtccctgg tgggcagttt catcattgtt ggtgtggctg 6960
taggcatctt cctgtgcaca ggtggacccg gatgttaattt actctccagc cccgtcagaa 7020
ggggctggat tggatggaggc tggcaagggaa aagtttcagc tcactgtgaa gccagactcc 7080
ccaactgaaa caccagaagg ttggagtgaa cagtcctttt cttctccac atctgcccac 7140
tgaagatttggaggaggaa gatggagagg agaggtggac aaagtacttg gtttgctaaag 7200
aacctaagaa cgtgtatgtt ttgctgaattt agtctgataa gtgaatgtttt atctatctt 7260
gtggaaaaca gataatggag ttggggcagg aagcctatgg cccatccccc aaagacagac 7320
agaatcacct gaggcgttca aaagatataa ccaataaaac aagtcatcca caatcaaaat 7380
acaacatcca atacttccag gtgtgtcaga cttgggatgg gacgctgata taataggta 7440
gaaagaagta acacgaagaa gtgggtggaaa tgtaaaaatcc aagtcatatg gcagtgatca 7500
attattaatc aattaataat attaataaaat ttcttataatt taaggcattt ttatctccctc 7560
cactttgcaa aatttcttggaa aaagtaacccctt ataccctt cttctgctt cttatttctc 7620
actcattttt tttttttttt tttttttttt ttgagacaga gtcttgctt gttgcctagg 7680
ctggagtgcata atgtgtgtat ctcagctcac tgcaacccctt gcctcccggt tcaagcaattt 7740
ctccctgcctc agccctcccaa gcagctggaa ttacagatgc atgccaccac acccagctaa 7800
tttttgtatt tttagtagag atggggtttcc accacgttgg ccatcctgac ctcgtatcc 7860
gcctaccccg gcctccccaa gtgtgggat tagacgtgag ccactgcgcc tgggtttctc 7920
actcattttt agacccagtg caatctgact tctctataaa ctactctaag atcaccagta 7980
acctctaattt gtcaaaccgt cacccttacat ggtatctgca aatttgcggaa ctagaactct 8040
tttttgccct taacttcttgc gataccatac ttcaattttt aaaactgtttc tggctacttt 8100
ttttcaatcc ctttgactat gtcaccccttac acgatttccacc ctggaaatgc tggcttcctt 8160
agaatttcc 8167

<210> 2
<211> 8167
<212> DNA
<213> *Homo sapiens*

```

<400> 2
aaatgaaata ttccaggctg tgcacagtgg ctcaaggcttg taatcccagc atttggggag 60
gctgaagtgg gcggtacacc tgaggtcagg agtttgagac caacctggcc aacatggta 120
aatccatct ctactaaaaaa tacaaaaatt agccagggtgt ggtggcagggt gactgtatc 180
ccagctactt gggaggctga ggcaggagaa tcgcgttgaat ctgggaggtg gaggtgcag 240
tgagccgaga tcacgcccact gcatacagca agactccatc tcaaaaaaaaaa gaaaaaaaaa 300
aagaaaaaaag aatgtttca taatttttaa taaaaggcaaa gacaatataa attggtagtt 360
attnaagtca ttctactttt cctgaggccc agtgcaggaa aacaaagtcc ctatccttgt 420
tccaaactaga ccattttgat aagctgcaaa aagaaaaagac ttgtatgcta ttcttagcc 480
agtttgcAAC agctgagagg tgagcatgga agctcttgcata tatattcagt tcagagaatg 540
gggtgccttagt ttatgtccag agtttgccttcc agatttcaact atgacgtcag ctctccgggg 600
agaagtatat aaaataaaaaa gttaaaatcc ctctcagtcc ttacccaaat cctattcccc 660
agaggttaatc tctattgaca gtacccctcc agatatttc cctatgtata tacaatata 720
cagatacaca ctgaaagtttta attttggccca ggtgcagtgg ctccgtccta taccagagga 780
ttgttgcgttgcgttgcaggatcc aagaccagcc tggcaacat agcgagacca catctctagt 840
aaaaataaaaaa aaaaaatagc taggcgttgcgttgcaggatcc cacgtacccaaat tacaatttgc 900
tactcggttgcgttgcgttgcaggatcc gagaatcaact tgagccgggg aggtcaagcc tacaatttgc 960

```


fc COPY

gggtgaaaaa ggaggcagaa aggagtgtct cttccactgc aggccctcagt ttccctcatct 4680
gtaaaacgga gataataatc cctgtccgt ctcctggca gagttactgt cagcgtcaaa 4740
cgggagaagc ggtgggaggg cacattatacg tttatgaagg gtcgagaagg cgggcggcca 4800
gcctcgaggt agggggttat tatcttccgc tgcccgcgc cccctccac gccggccag 4860
gctgaagttg actctgccc caggcctcca aagacttcat atgctccaga tctcctactt 4920
ccgcgacccc tatacagtgt ggtaccaggc caacgcgtcg ctgggggac acctaacgca 4980
cgtgctggaa ggcccagaca ccaacaccac gatcattcag ctgcagccct tgcaggagcc 5040
cgagagctgg ggcgcacgc agagtgccct gcaagtcctac ctgctccagt tccacggcct 5100
cgtgcgcctg gtgcaccagg agcggaccc tggcctgtgag taggcgcgca gccccccgg 5160
ggtctggcg gggctagtgg gggcggggccc tggcggtgg gggcggggccc tggcgatgg 5220
aggcgggctg gggcttgca gggcccgca gccactggag ctgggtggcg cctggcctt 5280
tgaagattgc tgggtggggg ctggagagag gcagttgtcc cgcctaagaa agccccact 5340
cgggcggctg tcctgctggc ataacctt gggatagacc ctgttggaa gccctgacac 5400
cgtgacgtcg aaggccccca gaaaactcct caccctcgc ctcacagtcc tccaaactcct 5460
tttcttcata gatctccgtc cttcccttcc cacagcccccc agcaacttcac ccccccaccc 5520
ccagccactt ctcataacaag ctgatgact cgctcttagc tccactcatg acccgaactc 5580
ttcccccaaa gaccccaagt tcttcctca aagccccact cttcccccgt cacaacccta 5640
actccttctt ctcataagacc ccaatttctt ttctcaaagc accaagcacc actccgtccc 5700
ccttccccca ccatcatggc ctttaattcc tttctctccct agtccccccac cccacccct 5760
ttttttttt tttttttttt ttttttttag acggagtctt gctctgtcg ccaggctgga 5820
gtgcagtggc gcatctcg ctcactgcaa cttccgcctc cccgggttcaa gcatgttcc 5880
tgcctcagcc tcccaagcag ctgggactac aggccccccg caccacgccc ggctaatttt 5940
ttgtatTTT agtagagacg gggtttcgca atgttggcca ggctggctc gaactcctga 6000
cctcaggcga tccacaagcc tggcctccca aagtgttggg attacaggcg tgagctgccc 6060
ccccctccccc agectcaccc cctgtttttt tttcttattt cagttgaaca aggctgaca 6120
atcccctttt ttcatcacag tccctggccc cttctttctt agcctctaacc aggttaaccc 6180
caaacccttc ctcacagccc caggcccttc tcccatagt tccctgaccc agactcccc 6240
ctcctcacag cactgactct tgcctctca tggcttttc ccctgggtgg gcctcgcccc 6300
acacccggca ccctctctgc acagtcctt gatcctgact gtctatccac agttctctg 6360
accatccgct gtttctggg ctgtgagctg cttcccgagg gctctagagc ccatgtcttc 6420
ttcgaagttt ctgtgaatgg gagtcctttt gtgagttcc ggccggagag agccttgg 6480
caggcagaca cccaggtcac ctccggagtg gtcacccctca ccctgcagca gctcaatgcc 6540
tacaaccgca ctccgtatga actgcgggaa ttccctggagg acacctgtgt gcaagtatgt 6600
cagaaacata ttcccgccgaa aacacacgaaa ggtatgtgg gacggggccc aggctgcaa 6660
gctggggaga gggcggttcc cagacaatg gatggacctg aaggatggat gcctagagca 6720
acaagagggc cacagctggg gtttgggac agaacacacg cagttcagt cagttggtaa 6780
acgggtccct ttccctctggg gcagaaacgc tttgggttt gactcaaattc atggactct 6840
tggggcccta ttccctgggc taactctttt catgttctgc agggagccaa acaaggccgt 6900
cctacacttc gctggcctg ggcgtcctgg tggcggttt catcattgc ggtgtggctg 6960
taggcacatctt cctgtgcaca ggtggacggc gatgttaattt actctccagc cccgtcagaa 7020
ggggctggat tggatggaggc tggcaaggga aagttcagc tcactgtgaa gccagactcc 7080
ccaactgaaa caccagaagg tttggagtga cagtcctttt cttctccac atctgcccac 7140
tgaagatttg agggaggggg gatggagagg agaggtggac aaagtacttg gtttgcataag 7200
aacctaagaa cgtgtatgtt ttgctgaattt agtctgatata gtgaatgtttt atctatcttt 7260
gtggaaaaca gataatggag ttggggcagg aagcctatgg cccatcctcc aaagacagac 7320
agaatcacct gaggcgttca aaagatataa ccaaataaac aagtcatcca caatcaaaat 7380
acaacattca atactccatg gtgtgtcaga cttggatgg gacgctgata taataggta 7440
gaaagaagta acacgaagaa gtggggaaa tgtaaaatcc aagtcatatg gcaagtatca 7500
attattaatc aattaataat attaataat ttcttatatt taaggcattt ttatctccct 7560
cactttgcaaa aatttctggaa aagtaaccc ataccattt cttctgttc cttatttctc 7620
actcattttt tttttttttt tttttttttt ttgagacaga gtcttgcctt gttgcctagg 7680
ctggagtgca atgggtgtat ctcagctcac tgcaacccctt gcctccgggt tcaagcaatt 7740
ctccctgcctc agcctccaa gcaagctgggaa ttacagatgc atgcccaccac acccagctaa 7800
tttttgtatt tttagtagag atggggtttc accacgttgg ccatcctgac ctcgtatcc 7860
gcctacctcg gcctcccaa gtgctggat tagacgtgag ccactgcgc tggcttctc 7920
actcattttt agacccatgtt caatctgact tctctataaa ctactctaag atcaccatgt 7980
acctctaattt gtcaaaaccgtt cacccttacat ggtatctgca aatttgcggg ctagaactct 8040
cttttgctt taacttctga gataccatac ttcaatTTT aaaactgttc tgcactttt 8100
tttcaatcc ctttgactat gtcatcttac acgattcacc ctggaaatgc tggcttccctt 8160
agaattc 8167

 COPY

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 3
gctgaagtgg gcggatcacc 20

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 4
tctagcctgg gtcatgcggc 20

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 5
tcttgccgca tgaccaggc 20

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 6
ggaaggaggc caggagatgg 20

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 7
ctcttactaa gggtgacgacg 20

q c COPY

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 8
tctgatgccc cacgagacac 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 9
tctctacagg gcaggcagag 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 10
tcgtgggtt ggtgtctggg 20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 11
aggagtgtct cttccactgc 20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 12
cttgtatgag aagtggctgg 20

<210> 13

fc COPY

<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 13
cccagacacc aacaccacga t 21

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 14
gtctgtcttt ggaggatggg 20

<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 15
agaggtggac aaagtacttg g 21

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 16
ggaagccagc atttccaggg 20

<210> 17
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 17
cctacacttc gctggtcctg ggcgtcctgg tctgc 35

<210> 18
<211> 22

 COPY

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR primer

<400> 18
caagtacttt gtccacacctcc

22



UNITED STATES PATENT AND TRADEMARK OFFICE

COPY

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
PO Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/573,804	Martine Aiach	P08898US00BAS
INTERNATIONAL APPLICATION NO.		PCT/IB04/03146
881 STITES & HARBISON PLLC 1199 NORTH FAIRFAX STREET SUITE 900 ALEXANDRIA, VA 22314		I.A. FILING DATE PRIORITY DATE 09/28/2004 09/29/2003
RECEIVED FEB 22 2007 STITES & HARBISON PLLC CONFIRMATION NO. 9377 371 FORMALITIES LETTER  *OC000000022559297* 4-21-2007		

Date Mailed: 02/21/2007

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 03/28/2006
- Copy of the International Search Report filed on 03/28/2006
- U.S. Basic National Fees filed on 03/28/2006
- Priority Documents filed on 03/28/2006

COPY

The applicant needs to satisfy supplemental fees problems indicated below.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Additional claim fees of \$360 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$490** for a Large Entity:

- \$130 Surcharge.

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

- Total additional claim fee(s) for this application is \$ 360

- \$360 for multiple dependent claim surcharge.

CCOPY

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

cc COPY

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

ANITA D JOHNSON

Telephone: (703) 308-9140 EXT 226

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/573,804	PCT/IB04/03146	P08898US00BAS

FORM PCT/DO/EO/905 (371 Formalities Notice)

COPY

COPY

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)		Docket No.	
		1 st Inventor	
		COMPLETE IF KNOWN	
<input type="checkbox"/> Declaration Submitted with Initial Filing <input type="checkbox"/> Declaration Submitted after Initial Filing		Appl. No.	
		Filing Date	

I hereby declare that:

Each inventor's residence, mailing address and citizenship are as stated below next to their name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Identification of polymorphisms in the EPCR gene associated with thrombotic risk.

the specification of which:

is attached hereto

OR

was filed on September 28, 2004 as PCT International Application No. PCT/IB2004/003146
 and (if applicable) was amended on .

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim FOREIGN PRIORITY benefits under 35 USC 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's certificate(s), or 365(a) of any PCT international application which designated at least one country other than the US, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed. (Additional applications listed on supplemental sheet provided herewith)



Prior Foreign Appl. No.	Country	Filing Date (Day/Month/Year)	Priority Not Claimed
03292392.2	EUROPE	29.09.2003	Yes

Power Of Attorney & Correspondence Address Indication

I hereby appoint the practitioners (of **Stites & Harbison PLLC**) associated with **CUSTOMER NUMBER 00881**
 as my/our attorneys or agents to prosecute the application identified above, and to transact all business in the US Patent and Trademark Office connected therewith.

Please direct all correspondence to the noted Customer Number.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. (Additional inventors named on supplemental sheet provided herewith)

SOLE OR FIRST INVENTOR		Citizenship	French
Given Name (First and Middle if any)	Martine	Family Name or Surname	AIACH
Full Mailing Address	70 rue Brancas – 92310 SEVRES - FRANCE		
Residence - City, State/Country (if different from mailing address)	“same as above”		
SIGN AND DATE HERE	Inventor's Signature 	Date	April 3, 2006
SECOND JOINT INVENTOR (if any)		Citizenship	French
Given Name (First and Middle if any)	Sophie	Family Name or Surname	GANDRILLE
Full Mailing Address	197 rue de Lourmel – 75015 PARIS - FRANCE		
Residence - City, State/Country (if different from mailing address)	“same as above”		
SIGN AND DATE HERE	Inventor's Signature 	Date	April 3, 2006
THIRD JOINT INVENTOR (if any)		Citizenship	French
Given Name (First and Middle if any)	Béatrice	Family Name or Surname	SAPOSNIK
Full Mailing Address	85 avenue du Général Michel Bizot – 75012 PARIS - FRANCE		
Residence - City, State/Country (if different from mailing address)	“same as above”		
SIGN AND DATE HERE	Inventor's Signature 	Date	April 5, 2006

COPY

Customized PTO/SB/01 (08-03)

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)		Docket No.	
SUPPLEMENTAL SHEET (use as required)		1 st Inventor	
		COMPLETE IF KNOWN	
		Serial No.	
		Filing Date	

Additional Prior Foreign Application(s):			
Prior Foreign Appl. No.	Country	Day/Month/Year Filed	Priority Not Claimed

Name Of Additional Joint Inventor, if any		Citizenship	French
Given Name (First and Middle [if any])	Pascale	Family Name or Surname	GAUSSEM
Full Mailing Address	8 rue du Général Castelnau – 94240 L'HAY LES ROSES - FRANCE		
Residence - City, State/Country (if different from mailing address)	"Same as above"		
SIGN AND DATE HERE	Inventor's Signature	Date APRIL 5th, 2006	

Name Of Additional Joint Inventor, if any		Citizenship	French
Given Name (First and Middle [if any])	Joseph	Family Name or Surname	EMMERICH
Full Mailing Address	112 rue Rambuteau – 75001 PARIS - FRANCE		
Residence - City, State/Country (if different from mailing address)	"Same as above"		
SIGN AND DATE HERE	Inventor's Signature	Date April 3, 2006	

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle [if any])		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle [if any])		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle [if any])		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

Name Of Additional Joint Inventor, if any		Citizenship	
Given Name (First and Middle [if any])		Family Name or Surname	
Full Mailing Address			
Residence - City, State/Country (if different from mailing address)			
SIGN AND DATE HERE	Inventor's Signature	Date	

COPY

INFORMATION DISCLOSURE STATEMENT	Application # 10/573,804
	Confirmation # 9377
	Filing Date 03/28/06
	First Inventor AIACH
	Art Unit
	Examiner
	Docket # P08898US00/BAS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR:

This IDS is submitted pursuant to 37 CFR. §1.97-1.98 and includes the following:

- A listing of the references on PTO-1449.
- A copy of all **non-US** references which are listed on the PTO-1449 (US refs not required).
- A copy of a corresponding foreign **Search Report** which explains the relevance of the references noted therein.
- A separate **explanation of relevance**.

Please note the following particulars concerning the filing of this IDS:

- 1. This IDS is filed at whichever is the latest of:
 - within three months of the filing date of a NATIONAL APPLICATION other than a CPA, or
 - within three months of the date of entry into the NATIONAL STAGE as set forth in 37 CFR. §1.491 in an international application, or
 - before the mailing date of a first Office Action on the merits or after filing of an RCE (*but if a first Office Action is mailed but not yet received and the date on the face of the attached foreign communication makes it evident that this IDS is submitted within three months from the mailing of the search report, then applicant is entitled to have this IDS considered under 2.B. below and such boxes should be considered as having been checked*).
- 2. This IDS is filed after a first Office Action, but before a Final Action, Allowance, or any other action which closes prosecution, and:
 - A. Is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).
 - B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
 - C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.
 - D. An appropriate Statement is attached.

3. This IDS is filed **after** a final action or allowance, but on/before payment of the issue fee, and:

A. is accompanied by a payment in the amount of \$180.00 required by 37 CFR. §1.17(p).

and

B. I hereby state that each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

C. I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.

D. An appropriate Statement is attached.


4. This IDS does not comply with 37 CFR 1.97-1.98, and is being filed **for placement in the file** pursuant to 37 CFR. §1.97(i)..

5. It will also be appreciated that:

- a. It is believed that this IDS complies fully with 37 CFR 1.56 and 1.97-98 and with MPEP § 609; but if for some reason it does not and will not be entered, the examiner is requested to telephone the undersigned so that any deficiency can be timely remedied.
- b. Some of the documents may have markings thereon, but no significance should be attached to those markings.
- c. These documents are not necessarily analogous art.
- d. Where an English language translation of an abstract is provided from a public source, applicant cannot vouch for the accuracy of that translation.

6. If no payment is enclosed and a fee is due in connection with this communication or if the payment enclosed is insufficient, the Director is authorized to charge any fee or additional fee due with this communication to Deposit Account No. 12-0555.

Respectfully submitted,



By: B. Aaron Schulman
Registration No.: 31,877

Date: May 21, 2007

STITES & HARBISON PLLC ♦ 1199 North Fairfax St. ♦ Suite 900 ♦ Alexandria, VA 22314
TEL: 703-739-4900 ♦ FAX: 703-739-9577 ♦ CUSTOMER No. 00881

Substitute for Form 1449A/PTO		Application #	10/573,804
		Confirmation #	9377
		Filing Date	03/28/06
		First Inventor	AIACH
		Art Unit	
		Examiner	
Sheet 1 of 1		Docket #	P08898US00/BAS

U.S. PATENT DOCUMENTS

Exam. Initial*	Document No. Number - Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.
	US-			

FOREIGN PATENT DOCUMENTS

Exam. Initial*	Country-Number-Kind	Publ. Date MM-DD-YYYY	Name Patentee or Applicant	Relevance Passages/Figs.	Trans- lation

NON PATENT LITERATURE DOCUMENTS

Exam. Initial*	Include NAME of the author (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., Publisher, City and/or Country where published	Trans- lation
	HAYASHI et al, "Organization and chromosomal localization of the human endothelial protein C receptor gene." Oct. 1, 1999, pp. 367-373, vol. 238, no. 2	
	ESPANA et al, "A new polymorphism in the 3' UTR region of the endothelial protein C receptor associated with increased levels of circulating activated protein C and decreased risk of venous thrombosis", 2001, pg. 0C885, Thromb. Haemost.	
	MEDINA et al, "the 4678G/C polymorphism in the endothelial protein C receptor (EPCR) gene is associated with levels of soluble plasma EPCR", July 2003, p. P0026, vol. 1	
	DATABASE SNP "Online! NCBI: database accession no. RS2069945	
	DATABASE SNP "Online! NCBI: database accession no. RS867186	
	DATABASE SNP "Online! NCBI: database accession no. RS2069944	
	DATABASE SNP "Online! NCBI: database accession no. RS2069948	
	DATABASE SNP "Online! NCBI: database accession no. RS945960	
	DATABASE SNP "Online! NCBI: database accession no. RS2069950	
	DATABASE SNP "Online! NCBI: database accession no. RS9574	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* Examiner: Initial if considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

PTO
STAMPED RECEIPT

Application #	10/573,804
Confirmation #	9377
Filing Date	03/28/06
First Inventor	AIACH
Art Unit	
Examiner	
Docket #	P08898US00/BAS

PAPERS SUBMITTED

- Transmittal Form
- Amendment
- with Attachments
- Amendment/Response After Final
- with Attachments
- Petition for Extension of Time
- Response to Missing Parts
- Declaration
- Translation of Application
- Assignment
- Priority Document
- Fee of \$250 (CREDIT CARD - PTO-2038)
- Copy of Notice
-

COPY

- IDS: Including
 - List of References
 - Search Report
- 10 Refs. Transmitted
- Statement of Relevance
- Issue Fee Transmittal
- Publication Fee Transmittal
- Letter to Draftsman
- sheets of formal drawings
(figs.)
- Notice of Appeal
- Appeal Brief
-
-

PTO Receipt Stamp →

